Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
21.46-0.96 (-4.28%)
At close: 04:00PM EST
21.05 -0.41 (-1.91%)
After hours: 06:21PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close22.42
Open22.57
Bid21.00 x 900
Ask25.00 x 1100
Day's Range21.30 - 23.28
52 Week Range20.01 - 37.82
Volume152,885
Avg. Volume164,401
Market Cap1.68B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.83
  • Business Wire

    ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

    LAUSANNE, Switzerland, November 09, 2021--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th at 11:20 a.m. GMT / 6:20 a.m. EST.

  • Business Wire

    ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting

    LAUSANNE, Switzerland, November 04, 2021--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced abstracts for ZYNLONTA® and ADCT-602 have been accepted for presentations at the 63rd American Society of Hematology (ASH) Annual Meeting, which will be held virtually and in Atlanta, Georgia

  • Simply Wall St.

    Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 50%?

    Today we will run through one way of estimating the intrinsic value of ADC Therapeutics SA ( NYSE:ADCT ) by estimating...

Advertisement
Advertisement